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ABSTRACT 
CANNABIS USE AND AFFECTIVE PROCESSING: A BRAIN STRUCTURE ANALYSIS 
 
by 
Kristin E. Maple 
 
The University of Wisconsin—Milwaukee, 2016 
Under the Supervision of Professor Krista Lisdahl 
 
Cannabis is the most commonly used illicit drug amongst adolescents and young adults 
in the United States. Previously, cannabis and its components have been associated 
with differences in affective processing and neural functioning. Participants (ages 16-25) 
were cannabis users and non-users excluded for psychiatric disorders, major medical 
conditions, and excessive other drug use. A series of multiple regressions examined 
whether past year cannabis use and cannabis x gender predicted measures of 
emotional face processing (using the PennCNP affective battery) as well as volumes in 
bilateral prefrontal, temporal, limbic, and cerebellar regions, as well as frontolimbic white 
matter tracts. Subsequently, Pearson correlations were conducted within the cannabis 
group to assess whether brain regions significantly associated with cannabis use 
predicted mood and affective processing. Increased cannabis use was associated with 
higher Acuity Neutral scores, smaller left rostral anterior cingulate (rACC) volumes, 
larger superior temporal volumes, and reduced right uncinate fasciculus mean 
diffusivity. Significant cannabis x gender interactions were observed for left rACC and 
forceps minor fractional anisotropy (FA). Greater cannabis use was associated with 
smaller left rACC volumes only within females, as well as greater forceps minor FA in 
females and reduced FA in males. Within the cannabis-using group, smaller rACC 
	  	   iii 
volumes were correlated with lower Emotion Discrimination Correct scores. These 
findings suggest that cannabis use exerts dose dependent effects on frontolimbic 
circuitry, which are in turn associated with deficits in affective processing. This may be 
one potential mechanism underlying high comorbidity rates between chronic cannabis 
use and psychiatric disorders.  
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Cannabis Use and Affective Processing: A Brain Structure Analysis 
 
     Cannabis is the most commonly used illicit drug in the United States, with 35.1% of 
12th graders and 31.6% of 19-28 year-olds using in the past year (Johnston et al., 
2015a; Johnston et al., 2015b). Furthermore, the perceived risk of using cannabis has 
dropped substantially amongst this population since 2005 (Johnston et al., 2015a; 
Johnston et al., 2015b). This decrease in perceived risk has occurred in parallel with 
many states proposing, and some passing, legislation to legalize medicinal and 
recreational cannabis use. Currently, recreational use is legal in Colorado, Washington, 
Oregon, Alaska, and Washington, D.C. Experts have predicted that with legalization, the 
price of cannabis is likely to drop, and consumption is likely to increase (Caulkins et al., 
2012). Given that cannabis use is widespread and may increase further, research on its 
potential neurocognitive effects in young people is critical.  
     Adolescents and emerging adults may be especially vulnerable to the negative 
effects of cannabis use due to the substantial neurodevelopment occurring during this 
period (Lisdahl et al., 2013; Lisdahl et al., 2014; Jacobus & Tapert, 2014). Although at 
age six the brain is approximately 90% of its adult weight, neurodevelopment continues 
into the late 20’s (Casey, Jones, & Hare, 2008). White matter volume and integrity 
increase, enhancing neural efficiency (Giedd et al., 1999; Lebel et al., 2008; Lebel & 
Beaulieu, 2011). The adolescent brain also undergoes significant synaptic pruning in 
regions associated with higher-order and executive function, such as the prefrontal 
cortex (PFC) (Casey et al., 2008). The PFC is one of the last areas to mature, lagging 
behind subcortical limbic regions involved in affect, such as the amygdala (Casey et al., 
2008). According to Casey and colleagues’ (2008) model, when adolescents are 
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presented with an emotionally-charged situation, limbic regions will override the 
prefrontal executive system, leading to increased risk taking, impulsivity, and emotional 
reactivity. Thus, adolescents may be more likely to engage in risky behavior such as 
substance use, and are at greater risk of developing a substance use disorder 
compared to those initiating use as adults (Chambers et al., 2003; Casey et al., 2008; 
Bava & Tapert, 2010). Given the increased likelihood to abuse substances, including 
cannabis, during a time when the brain is particularly vulnerable to their neurotoxic 
effects, adolescence and emerging adulthood is the ideal period to research and target 
substance use interventions (Squeglia, et al., 2009; Lisdahl et al., 2013). 
The Endogenous Cannabinoid System: Neurodevelopment & Affective 
Processing 
     The main psychoactive component of cannabis, Δ-9-tetrahydrocannabinol (THC), 
exerts its effects by binding brain cannabinoid receptor-1 (CB1) in the endocannabinoid 
(eCB) system (Howlett, 1995). Cannabidiol (CBD) is another cannabinoid found in 
herbal cannabis, but typically in low doses. In cannabis, THC content is typically much 
higher compared to CBD, with published mean THC levels at 8.8% and CBD at 0.4% in 
the U.S. in 2008 (Mehmedic et al., 2010). A more recent report of cannabis seized in 
Australia noted 14.88% THC (Swift et al., 2013). Recent research has suggested that 
CBD may antagonize some negative effects of THC, such as anxiety (Niesink & van 
Laar, 2013).   
     CB1 receptors are located on pre-synaptic terminals of both excitatory and inhibitory 
neurons, as well as on glial cells, including astrocytes, microglia, and oligodendrocytes 
(e.g., Domenici et al., 2006; Pazos et al., 2005).  The eCB system includes the primary 
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ligands anandamide (AEA) and 2-AG, which also bind CB1 (Mechoulam & Parker, 
2013). After AEA interacts with CB1 at the pre-synaptic terminal, it is degraded by the 
enzyme fatty acid amide hydrolase (FAAH) (Ho & Hillard, 2005). Thus, higher levels of 
FAAH are typically associated with lower levels of eCBs (Giang & Cravatt, 1997). 
     From prenatal stages through adulthood, the eCB system influences 
neurodevelopment (e.g., Aguado et al., 2006; Berghuis et al., 2007; Mulder et al., 2008; 
Schneider et al., 2008; Chadwick et al., 2013). Activation of CB1 receptors can initiate a 
signal transduction pathway that affects developmental processes, such as synaptic 
plasticity, cell migration, axon guidance, and neuronal growth (Pazos et al., 2005; 
Mechoulam & Parker, 2013; Melis et al., 2014; Zhou et al., 2014). The eCB system is 
dispersed throughout the brain and undergoes dynamic changes throughout 
neurodevelopment (Chadwick et al., 2013). CB1 receptors are highly expressed in the 
PFC, cingulate cortex, hippocampus, amygdala, basal ganglia, and cerebellum, with 
relatively low levels in the brainstem (Herkenham et al., 1990; Glass et al., 1997; 
Mackie et al., 2005; Svizenska et al., 2008). While distribution of CB1 receptors stays 
relatively constant across development, density is altered over time (Glass et al., 1997); 
expression of CB1 mRNA and CB1 density and binding are highest during puberty 
onset and adolescence, decreasing by adulthood (Ellgren et al., 2008; Schneider, 2008; 
Heng et al., 2011; Chadwick et al., 2013; Higuera-Matas et al., 2015). This pattern is 
particularly evident in the medial PFC, cingulate cortex, and insula, which demonstrate 
the most dramatic and progressive decrease in CB1 expression across adolescence 
(Heng et al., 2011). This decline in CB1 levels occurs in tandem with an increase in 
AEA and decrease in 2-AG within the PFC (Ellgren et al., 2008). These differences in 
	  	   4 
eCB activity across adolescence, particularly in maturing prefrontal regions, indicate a 
role for this system in the neurodevelopmental processes occurring during this period. 
Therefore, age-related changes in eCB functioning indicate that adolescents and 
emerging adults may be at greatest risk to incur the negative consequences of cannabis 
exposure (Higuera-Matas et al., 2015). 
     The eCB system, among other functions (e.g., sleep, pain, memory, feeding, and 
inflammation), modulates mood and stress response. Indeed, genetic variants in the 
eCB system, including multiple FAAH and CNR1 (gene coding for CB1) single 
nucleotide polymorphisms, are associated with both subclinical depressive symptoms 
and mood disorders in humans (Maple et al., in press; Barrero et al., 2005; Monteleone 
et al., 2010; Mitjans et al., 2013). Moreover, several rodent studies have revealed that 
increases in eCB activity elicit antidepressant and anxiolytic responses, while decreases 
in activity lead to depression (Martin et al., 2002; Hill et al., 2005; Hill & Gorzalka, 2005; 
Gobbi et al., 2005; Bortolato et al., 2007; Naidu et al., 2007; Serra & Fratta, 2007; 
Adamczyk et al., 2008; McLaughlin & Gobbi, 2012). Steady eCB tone in the mPFC 
prevents unnecessary limbic and HPA activation, promoting positive emotionality and 
healthy coping responses to stress (McLaughlin, Hill, & Gorzalka, 2014). However, 
under chronic, unpredictable stress, eCB tone in the mPFC can decrease, leading to 
HPA hyperactivation. Indeed, this heightened HPA activity increases vulnerability to 
anxiety and mood disorders (McLaughlin et al., 2014). This suggests a crucial role for 
the eCB system in modulating frontolimbic activity in response to stress.  
     More specifically, evidence suggests that the eCB system is associated with facial 
emotion processing. Studies have demonstrated that both FAAH (Hariri et al., 2008) 
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and CNR1 (Chakrabarti et al., 2006) genotypes modulate brain activation to emotional 
faces. Recognizing and interpreting facial expressions is a critical aspect of functioning 
in human social networks. Facial expressions provide information about an individual’s 
emotional state, and interpretation of these expressions by others can elicit an 
emotional state in response (Phillips et al., 2003; Bourke et al., 2010). Therefore, it is 
possible that any inaccuracy in identifying facial emotions may negatively influence 
one’s affective state and emotional well-being (Phillips et al., 2003). In addition, mood 
may bias one’s appraisals regarding facial emotions, therefore perpetuating a cycle of 
appraisals impacting emotional responses, which in turn influence further appraisals 
(e.g., Mogg et al., 2000; Joormann & D’Avanzato, 2010; Duque & Vazquez, 2015). In 
fact, abnormal facial emotion processing is common in those with psychiatric disorders, 
including major depressive disorder (MDD), bipolar disorder, social anxiety disorder, 
and schizophrenia (e.g., Marwick & Hall, 2008; Morris et al., 2009; Bourke et al., 2010; 
Stuhrmann et al., 2011; Staugaard, 2010; Samame, 2013).  
Cannabis & Affective Processing 
     Considering the critical role the eCB system plays in modulating mood, and its 
apparent role in processing facial emotions, it is unsurprising that both acute and 
chronic exposure to exogenous cannabinoids, including THC and CBD, can alter 
affective functioning. Multiple studies have found that acute THC administration 
significantly impairs participants’ emotion identification abilities (Ballard et al., 2012; 
Bossong et al., 2013; Hindocha et al., 2015), while CBD enhances accuracy (Hindocha 
et al., 2015). Acute THC administration affects neural activation to emotional faces in 
limbic (Phan et al., 2008; Bhattacharyya et al., 2010; Bossong et al., 2013), temporal 
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(Fusar-Poli et al., 2009), frontal, parietal, and occipital (Fusar-Poli et al., 2009; Bossong 
et al., 2013) areas. In response to emotional faces, CBD impacts activity in the left 
amygdala, anterior and posterior cingulate cortices, anterior parahippocampal gyrus, left 
middle occipital gyrus, and the cerebellum (Fusar-Poli et al., 2009; Bhattacharyya et al., 
2010). While some have found acute THC (Gorka et al., 2015) and CBD (Fusar-Poli et 
al., 2010) to impact frontolimbic connectivity, others have found no effect (Fusar-Poli et 
al., 2010). Cannabis smoking, which typically has substantially higher levels of THC 
compared to CBD (Mehmedic et al., 2010), leads to poorer acute emotion recognition 
(Clopton et al., 1979). Therefore, the current literature suggests that acute THC and 
CBD impact many frontolimbic and associated areas with high eCB activity during facial 
emotion processing. 
     Chronic cannabis exposure is associated with long-term affective and mood 
problems. Cannabis users score higher on measures of anxiety and depression 
compared to non-using controls (Troisi et al., 1998; Dorard et al., 2008; Medina & 
Shear, 2007; Medina et al., 2007; Wright et al., under review). In fact, cannabis use has 
a high rate of comorbidity with anxiety and mood disorders in both adolescents (e.g., 
McGee et al., 2000; Wittchen et al., 2007; Dorard et al., 2008) and adults (e.g., Troisi et 
al., 1998; McGee et al., 2000; Agrawal et al., 2011; Lev-Ran et al., 2013). A substantial 
number of studies suggest that cannabis use increases one’s risk for subsequently 
developing affective disorders, especially if use begins in early adolescence (e.g., 
Bovasso, 2001; Patton et al., 2002; Rey & Tennant, 2002; Hayatbakhsh et al., 2007; 
van Laar et al., 2007; de Graaf et al., 2010; Fairman & Anthony, 2012; Rasic et al., 
2013). Yet, other studies report anxiety and/or depression predicting later cannabis use 
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(e.g., Wittchen et al., 2007). Thus, the relationship between cannabis and affect is 
complicated and likely nuanced, especially given that many people reportedly use 
cannabis to ameliorate internalizing symptoms, such as depression and anxiety (Boys 
et al., 2001; Walsh et al., 2013). One mechanism underlying mood symptoms in 
cannabis users may be damage to the affective neural network, resulting in deficits in 
basic affective processing such as facial emotion processing. 
     A limited number of studies have investigated the relationship between chronic 
cannabis use and facial emotion processing. The available evidence suggests that 
cannabis users are significantly slower (Platt et al., 2010) and less accurate (Hindocha 
et al., 2014; Bayrakci et al., 2015) in identifying emotions compared to controls. Further, 
the ability of cannabis users to discriminate whether two faces show the same emotion 
is reduced (Bayrakci et al., 2015). Findings from another group suggest that lower levels 
of cannabis use might not be related to facial emotion processing, while more frequent 
and recent cannabis use is associated with affective processing deficits (Huijbregts et 
al., 2014). Chronic cannabis use has been associated with blunted ACC (Gruber et al., 
2009) and amygdala (Gruber et al., 2009; Cornelius et al., 2010) activation to negative 
facial emotions, while in younger (14 years of age) cannabis users, amygdala activation 
is increased (Spechler et al., 2015).  
Cannabis Use and Brain Structure Associated with Affective Processing 
     Morphometry Studies. Facial emotion processing is a complex process, recruiting 
many visual, limbic, temporoparietal, and prefrontal areas, as well as the cerebellum 
and putamen (Ishai et al., 2005; Fusar-Poli et al., 2009; Said et al., 2011). Further, 
many regions involved in facial emotion processing are high in CB1 receptor density, 
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including the PFC, cingulate cortex, amygdala, hippocampus, and cerebellum. Chronic 
cannabinoid exposure is associated with CB1 receptor downregulation in areas 
associated with affect, including cortical regions (McKinney et al., 2008; Hirvonen et al., 
2012), the hippocampus, and cerebellum (Villares, 2007; McKinney et al., 2008). This 
downregulation of CB1 receptors is likely one mechanism by which long-term cannabis 
use can impact affective processing differentially from acute exposure.  
     Although some studies have examined functional brain relationships underlying 
facial emotion processing in cannabis users, no known studies have investigated 
structural relationships associated with these differences. Yet, several researchers have 
examined basic brain structural differences related to cannabis use. Indeed, many of 
these structural differences have been found in regions classically associated with 
emotional face processing. Cannabis users have exhibited volumetric differences in the 
mOFC (Churchwell et al., 2010; Cheetham et al., 2012; Batistella et al., 2014; Price et 
al., 2015), total PFC (Medina et al., 2009), and fusiform gyrus (Jarvis et al., 2008). Only 
one known study has investigated superior temporal gyrus volume in cannabis users 
compared to non-users, yielding no difference between groups in either the right or left 
superior temporal gyrus (DeLisi et al., 2006). Cannabis use has also been associated 
with volume differences in subcortical affective regions such as the amygdala (Yucel et 
al., 2008; McQueeny et al., 2011; Schacht et al., 2012; Cousijn et al., 2012; Gilman et 
al., 2014; Pagliaccio et al., 2015), hippocampus (Matochik et al., 2005; Medina et al., 
2007a; Yucel et al., 2008; Ashtari et al., 2011; Demirakca et al., 2011; Schacht et al., 
2012; Cousijn et al., 2012; Solowij et al., 2013), and cerebellum (Jarvis et al., 2008; 
Medina et al., 2010; Solowij et al., 2011; Cousijn et al., 2012; Batistella et al., 2014; 
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Nurmedov et al., 2015). Most studies in emerging adult samples have demonstrated 
decreased volumes across brain regions in association with cannabis use (eg, Matochik 
et al., 2005; Yucel et al., 2008; Churchwell et al., 2010; Ashtari et al., 2011; Demirakca 
et al., 2011; Schacht et al., 2012; Cousijn et al., 2012; Solowij et al., 2013; Batistella et 
al., 2014; Price et al., 2015; Pagliaccio et al., 2015).  
     Some studies have reported increased volumes in association with cannabis use 
(e.g., Medina et al., 2009; Medina et al., 2010; McQueeny et al., 2011). However, these 
samples were comprised exclusively of younger adolescents (eg, 16-18 years). In these 
studies, increased volumes were associated with functional deficits such as poorer 
executive functioning and increased internalizing symptoms. The authors of these 
studies hypothesize that cannabis may interfere with significant synaptic pruning 
occurring during adolescence (Medina et al., 2009; Medina et al., 2010; McQueeny et 
al., 2011; Lisdahl et al., 2014). Further, gender may moderate these findings; 
adolescent females appear to be particularly vulnerable to the impact of cannabis on 
PFC and amygdala volumes (Medina et al., 2009; McQueeny et al., 2011). Despite this 
substantial literature, some studies have reported null findings for each of these brain 
regions (eg, Tzilos et al., 2005; Medina et al., 2007b; Ashtari et al., 2011; Cousijn et al., 
2012; Mashhoon et al., 2015; Pagliaccio et al., 2015; Smith et al., 2015; Lorenzetti et 
al., 2015; Price et al., 2015; Weiland et al., 2015). Thus, more research is needed to 
clarify how gender might moderate the relationship between cannabis use and PFC, 
limbic, and cerebellar volumes. 
     White Matter Integrity. As CB1 receptors are present on axons and 
oligodendrocytes (Domenici et al., 2006; Pazos et al., 2005), which comprise white 
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matter, exogenous cannabinoids may alter white matter functioning. Several diffusion 
tensor imaging (DTI) studies have found associations with cannabis use and white 
matter integrity in regions throughout the brain (e.g., Gruber & Yurgelun-Todd, 2005; 
DeLisi et al., 2006; Arnone et al., 2008; Ashtari et al., 2009; Bava et al., 2009; Allin et 
al., 2009; Bava et al., 2010; Gruber et al., 2011; Zalesky et al., 2012; Bava et al., 2013; 
Jacobus et al., 2013a; Jacobus et al., 2013b). Of particular note, Shollenbarger and 
colleagues (2015) found an association between cannabis use and decreased white 
matter integrity in the corpus callosum forceps minor, uncinate fasciculus, and anterior 
thalamic radiations (ATR). As the CC forceps minor, uncinate fasciculus, and ATR 
connect frontolimbic regions (Catani & Thiebaut de Schotten, 2012), reduced integrity in 
these tracts may be of particular relevance to affective processing. Reduced uncinate 
integrity has been associated with major depression (Bracht et al., 2015; Taylor et al., 
2007; Cullen et al., 2010; Dalby et al., 2010; Carballedo et al., 2012; Zhang et al., 2012) 
and poorer facial emotion recognition (Fuije et al., 2008). Similarly, several studies have 
associated integrity in the ATR (Henderson et al., 2013; Bessette et al., 2014; Lai & Wu, 
2014, Bracht et al., 2015) and CC forceps minor (e.g., Alves et al., 2014; Serafini et al., 
2014) with mood disorders. Thus, considering the association that the uncinate, ATR, 
and forceps minor have with affective disorders, it is possible they are involved in 
affective processing in cannabis users. Consistent with this, Shollenbarger and 
colleagues (2015) found that increased subclinical depressive symptoms in cannabis 
users were associated with decreased integrity in bilateral ATR and right uncinate 
fasciculus. However, more research is needed to determine if these tracts are 
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associated with specific aspects of affective processing, such as identifying facial 
emotions.  
Gender Differences 
     Evidence indicates that male and female brains may process affective information 
differently. Women have twice the rate of affective disorders as men (e.g., Gater et al., 
1998), and research findings suggest that healthy females are generally more accurate 
at identifying facial emotions compared to males (Kret & De Gelder, 2012). Further, 
males and females appear to recruit different networks while processing emotional 
faces (Killgore & Yurgelun-Todd, 2001; Killgore et al., 2001; Killgore & Yurgelun-Todd, 
2004; Whittle et al., 2011). Although the literature is not wholly consistent, females tend 
to exhibit increased temporal, ACC, and limbic activation while males demonstrate 
increased frontal and parietal activation to emotional faces (Hall et al., 2004; Kempton 
et al., 2009; Whittle et al., 2011). In addition, female affective circuitry may be more 
susceptible to the negative effects of cannabis use. For instance, compared to males, 
adolescent female rats exposed to THC are more vulnerable to its anxiety and 
depression producing properties (Rubino et al., 2008). In humans, female cannabis 
users have exhibited disadvantages in PFC and amygdala volumes compared to their 
male counterparts (Medina et al., 2009; McQueeny et al., 2011). Additionally within 
females compared to males, increased CB1 desensitization to THC is observed within 
frontolimbic regions, including the PFC, amygdala, and hippocampus (Crane et al., 
2013). Thus, cannabis-using females may process facial emotions differently from male 
users, and this may be related to underlying brain structure in frontolimbic regions.   
Aims and Hypotheses 
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     Despite evidence that chronic cannabis use may impact facial emotion processing in 
adolescents and emerging adults, few studies have examined affective processing in 
regular cannabis users and whether these relate to structural abnormalities in the 
affective processing network. Thus, the current study seeks to elucidate these 
relationships.  
     Primary Aims. (1) Cannabis Use and Affective Processing. We will investigate 
whether increased cannabis use or cannabis x gender predict affective processing and 
mood symptoms in adolescents and emerging adults. Specifically, we will examine 
whether these variables predict (a) facial emotion processing and (b) depressive 
symptoms. Based on the aforementioned literature, we hypothesize that cannabis users 
will have impaired emotional processing and increased depressive symptoms compared 
to non-users. It is predicted that females will be more susceptible to the potential effects 
of cannabis on (a) affective processing and (b) depressive symptoms compared to 
males.  
     (2) Cannabis Use and Brain Structure. We will assess whether cannabis use and 
cannabis x gender are associated with abnormal brain structure in regions underlying 
affective processing. (a) We will investigate whether cannabis use and cannabis x 
gender predict volumes of regions implicated in affective processing, including the 
bilateral medial orbital frontal cortex (mOFC), lateral orbital frontal cortex (lOFC), rostral 
ACC (rACC), caudal ACC (cACC), Pars triangularis, superior temporal gyrus, fusiform 
gyrus, amygdala, hippocampus, and cerebellum. Based on other studies with a similar 
mean age, we hypothesize that increased cannabis use will be associated with 
decreased gray matter volumes in prefrontal regions, superior temporal gyrus, fusiform 
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gyrus, amygdala, and hippocampus, as well as increased cerebellar volumes. 
Additionally, it is predicted that greater cannabis use in females will be associated with 
the most marked volumetric relationships. (b) We will also explore whether cannabis 
use and cannabis x gender predict white matter integrity in major frontolimbic tracts 
involved in affective processing: R/L uncinate fasciculus, R/L anterior thalamic 
radiations, and corpus callosum forceps minor. We hypothesize that higher levels of 
cannabis use will be associated with decreased white matter integrity in these regions. It 
is additionally predicted that females with more cannabis use will have the greatest 
reduction in white matter integrity. 
     Secondary Aim. Once we determine regions that are associated with either 
cannabis or cannabis x gender, we will determine if those areas predict (a) emotional 
processing and (b) depressive symptoms within the cannabis user group. We 
hypothesize that brain structure will predict affective processing and depressive 
symptoms within cannabis users. 
Method 
 
Participants 
     Participants included 77 (two of these did not complete the MRI scan due 
claustrophobia) cannabis using and non-using adolescents and emerging adults ages 
16-25 years, recruited from a larger parent study (R01 DA030354).  
     Recruitment. Individuals were recruited from the community. Flyers were posted 
around universities, cafes, bars, headshops, recreation centers and festivals. Best 
attempts were made to recruit an ethnically representative sample balanced for gender.          
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     Inclusion/Exclusion Criteria. Inclusion criteria. Inclusion criteria for cannabis use. 
Used cannabis at least 10 times in past three months or at least 50 times in life. 
Inclusion criteria for non-using controls. Used cannabis fewer than 50 times in life and 
fewer than five times in the past year. Exclusion criteria (both groups). Non-English 
speaker, left-handed, has non-removable metal (or any other MRI contraindication), 
younger than 16 years of age, older than 25 years of age, prenatal alcohol (>6 drinks 
per week or >4 per day) or nicotine exposure, birth complications, premature birth (<33 
weeks gestation), no neurological disorders (ie, seizures, migraines, tumors, 
chemotherapy, multiple sclerosis, movement disorders), head trauma with >2 minute 
loss of consciousness, learning disability, intellectual disability, vision or hearing 
impairments, major health problems, independent DSM-IV psychological disorder 
diagnosis (aside from substance use disorder), current use of psychoactive medication, 
using more than 10 cigarettes per day, heavy other drug use (>25 lifetime uses of non-
cannabis drugs), possible pregnancy, failure to remain abstinent from substances 
throughout the study (as indicated by positive urine toxicology and/or continuous sweat 
patch testing).  
     In order to assess inclusion and exclusion criteria, screening included both an initial 
and a detailed phone screen, each with both the youth participant and a parent/guardian 
(required for ages 16-17; highly preferable for ages 18-25).  
     Screening. Initial Screening. When a potential participant called in response to an 
advertisement, study staff obtained verbal consent/assent to conduct a 5-10 minute 
phone screen (if youth was younger than 18, study staff gained permission from a 
parent/guardian) with each the parent and youth separately to determine basic eligibility 
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with non-sensitive questions (eg, age, ethnicity, MRI contraindications, vision and 
hearing problems, yes/no questions about psychiatric history and yes/no questions 
about substance use).  
     Detailed Screening. Before conducting the 45-minute detailed phone screen, study 
staff obtained written consent/assent from participants and parents. Comprehensive 
substance use history (lifetime) was obtained from youth with the Customary Drinking 
and Drug Use Record (CDDR) (Brown et al., 1998; Stewart and Brown, 1995). 
Information regarding youth psychiatric history was gathered by administering the Mini 
International Psychiatric Interview (MINI) (Sheehan et al., 1998) to youth and parents. 
Youth and parents were informed if ineligible and each paid $20 upon completion of the 
detailed screen. To maintain study integrity, specific reasons for ineligibility were not 
disclosed to participants.  
Procedure 
     Eligible participants attended five study sessions over the course of four weeks. 
Sessions 1-3 were weekly sessions consisting of drug testing and brief 
neuropsychological testing. One week after Session 3, Sessions 4 and 5 were 
conducted within 24-48 hours of each other. Session 4 included a 3-hour 
neuropsychological battery, while Session 5 consisted of MRI scanning.  
     Verifying abstinence. Biological measures. Participants were expected to remain 
abstinent from alcohol and drugs throughout the course of the study in order to prevent 
acute intoxication. Thus, all participants were monitored for substance abstinence 
during each of five study sessions. At each session, participant abstinence was 
evaluated using urine toxicology, specifically the ACCUTEST SplitCup 10 Panel drug 
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test, which measured whether someone was positive or negative for amphetamines, 
barbiturates, benzodiazepines, cocaine, ecstasy, methadone, methamphetamines, 
opiates, PCP, and THC. Urine samples were also used to measure cotinine (metabolite 
of nicotine) levels with NicAlert. In addition to the urine toxicology, continuous sweat 
toxicology was conducted with the PharmChek Drugs of Abuse Patch, which tested for 
cocaine, benzoylecgonine, heroin, 6MAM, morphine, codeine, amphetamines, 
methamphetamine, THC, and phencyclidine. Furthermore, at each session, participants 
underwent breathalyzer testing for recent alcohol use. Participants who tested positive 
for any drugs, or who had a blood alcohol concentration of >.000 directly prior to 
Session 4 (extended neuropsychological battery) and Session 5 (MRI scanning) were 
removed from the study.  
Measures 
     Demographic Information. Participants completed a background questionnaire 
outlining demographic variables including age, gender, ethnicity, self and biological 
parents’ educations, incomes, and employments, marital status, history of medical or 
neurological illness, psychological disorders or use of psychiatric medication, and 
learning disability. 
     Substance use. During each session, participants were asked to report the last time 
they used alcohol, marijuana, cigarettes, or other drugs. In addition, at Session 3, 
participants were asked to complete the Timeline Follow Back (TLFB; Sobell & Sobell, 
1992). This is a highly reliable and valid measure of past year substance use, using 
holidays and other memory cues. As part of completing the TLFB, participants were 
asked to report the quantity of specific substances (e.g., alcohol, cannabis, nicotine, 
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etc.) used on each day during the past year. Substance use was measured in standard 
units (e.g., joints for cannabis). Lifetime and past 3-month substance use was measured 
using the Customary Drinking and Drug Use Record (CDDR), which also assesses 
withdrawal symptoms, DSM-IV abuse and dependence criteria, and substance-related 
difficulties (Brown et al., 1998; Stewart and Brown, 1995).  
     Self-reported Mood. Participants completed the Beck Depression Inventory-II (BDI-
II; Beck et al., 1996) at Session 4. This measure contains 21 items measuring past two-
week depressive symptoms on a 0-3 point scale. Total scores indicate either “minimal” 
depression (0-13), “mild” depression (14-19), “moderate” depression (20-28), and 
“severe” depression (29-63). Independent depressive disorders were excluded as part 
of the larger imaging study.  
     Affective Processing. During Session 4, participants completed an affective battery 
(PennCNP) containing three facial emotion processing tasks of interest to the current 
analysis: Emotion Recognition, Emotion Discrimination, and Emotional Acuity tasks. In 
Emotion Recognition, participants were presented with a series of faces (shown 
individually) and instructed to identify which emotion each face was expressing. 
Possible answer choices included happy, sad, anger, fear, and no emotion. The facial 
stimuli are described in Gur et al. (2002) and Pinkham et al. (2008). In the Emotion 
Discrimination task, participants were presented with pairs of faces, one pair for each 
trial. Each pair of faces contained two pictures of the same individual, with or without a 
subtle (computer-generated) change in facial expression, which may or may not have 
indicated a difference in intensity between the two facial emotions. During each trial, the 
participant had to decide which picture expressed the specified emotion (happy or sad) 
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more intensely, or whether they were equal. In the Emotional Acuity task, participants 
were presented with one face per trial. Faces were randomly presented and participants 
were instructed to rate the facial expression’s emotional valence on a 7-point scale: very 
sad, moderately sad, somewhat sad, neutral, somewhat happy, moderately happy, or 
very happy. Facial stimuli for the Emotion Discrimination and Emotional Acuity tasks are 
described in Erwin et al. (1992). As normative scores are not available for this battery, 
all analyses were conducted with raw scores.     
     MRI Data Acquisition. Participants were scanned on a 3T GE scanner at Medical 
College of Wisconsin (MCW) during Session 5, which was completed within 24-48 
hours of Session 4 (when affective measures were obtained). Structural Image 
Acquisition. This took approximately 15 minutes. A T1-weighted, 3-D anatomical brain 
scan was obtained with a modified driven equilibrium Fourier transform (MDEFT) 
sequence (TMD=1.1 s, TR=13 ms, FOV=25.6 x 19.2 x 19.2 cm., matrix 256 x 192 x 96 
pixels, flip angle=20 degrees). Diffusion Tensor (DTI) Image Acquisition.  DTI was 
obtained using 48 diffusion directions with b ≈ 700s/mm2 (FOV= 25.6 cm, 128 x 128 
matrix, resolution=4x4x4 mm, TR = 9,300 ms, TE = 81.4 ms (minimum), flip angle 90 ̊. 
     MRI Processing. Image Preprocessing. Structural images were initially 
preprocessed using the Analysis of Functional Neuroimages (AFNI) software package. 
This sequence included converting 2D slice data into a 3D dataset (BRIK and HEAD 
files). This file was then converted into a file readable by FreeSurfer (.mgz). Using 
FreeSurfer software, all T1-weighted 3D anatomical datasets underwent motion 
correction, non-parametric non-uniform intensity normalization, MNI transformation, 
removal of non-brain materials, and skull-stripping. This was followed by whole-brain 
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segmentation of white and gray matter and registration of anatomical brain regions. 
Automatic subcortical segmentation took place in six steps, including registration to a 
template, canonical normalization, canonical registration, neck removal, registration 
w/skull, and subcortical labeling. Bilateral cortical ROIs (mOFC, rACC, cACC, Pars 
triangularis, Pars orbitalis, OFC, superior temporal gyrus, fusiform gyrus) were 
parcellated using the Desikan-Killiany atlas (Desikan et al., 2006) in FreeSurfer. This is 
a gyral-based atlas; regions include a gyrus plus adjacent sulci. Using these ROIs, 
regional cortex volumes (in cubic millimeters) were obtained. In the current analysis, 
Pars orbitalis and OFC were combined to create the lateral OFC (lOFC) region. All 
automated FreeSurfer steps were inspected for processing errors, and manual edits 
were made as needed. For each case, automatic segmentation and parcellation masks 
were manually edited for accurate segmentation, using multiple views for visual 
inspection. 
     DTI Processing. Following whole-brain segmentation, the software program, Tracts 
Constrained by Underlying Anatomy (TRACULA) (within FreeSurfer) was used to 
analyze tractography data. TRACULA is a global probabilistic tractography program 
allowing reconstruction of white matter pathways from diffusion tensor images. This 
yields measures of white matter integrity, including fractional anisotropy (FA) and mean 
diffusivity (MD)  (Yendiki et al., 2011). Each image underwent the following 
preprocessing steps: (1) Image Corrections (e.g., for B0 inhomogeneities, eddy 
currents, and simple head motion), (2) Further head motion correction, (3) Intra-subject 
and Inter-subject registration (4) Mask creation (White matter is extracted from 
FreeSurfer’s segmentation and parcellation and combined into a mask), (5) Tensor fit, 
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(6) Estimation of pathway priors (the atlas data was combined with the individual’s own 
masks). Following this preprocessing, a ball-and-stick model of diffusion was fitted to 
the images. After diffusion measures in each voxel were determined by Markov Chain 
Monte Carlo sampling, likelihood of the locations of uncinate fasciculus, ATR, and 
corpus callosum forceps minor pathways within each individual were established. From 
these estimated pathways, statistics on diffusion measures (average weighted FA and 
MD) within each individual were extracted. We performed group analyses along the 
entire corpus callosum forceps minor, bilateral uncinate fasciculus, and bilateral anterior 
thalamic radiations tracts. For nine of these participants, forceps minor could not be 
adequately reconstructed in TRACULA. Thus, they were excluded from the regressions 
investigating forceps minor FA and MD. 
Data Analysis 
 
     Preliminary Analysis. All analyses were conducted in the statistical program SPSS. 
For each primary aim, demographic and other drug use was examined using ANOVA 
(or Mann-Whitney for any variables not normally distributed) and Chi-Square analyses 
to detect differences between cannabis users and non-users. Variables that either 
differed between groups or have known relationships with affective processing or brain 
structure were entered as covariates. For Aim 1, these included gender, past year 
alcohol use, and past year nicotine use. Aim 2 included these covariates as well as 
intracranial volume for volumetric analyses.  
     Principal Components Analysis (PCA) for Emotional Processing Tasks. We 
conducted three principal components analyses (PCA) to extract components from each 
of the Emotion Recognition, Emotion Acuity, and Emotion Discrimination tasks. 
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Accuracy and response time variables were selected for each task and entered into 
PCA (see Tables 2, 3, 4). 
     Primary Analysis. Aim 1. Multiple regressions (including appropriate covariates) 
were used to examine whether past year cannabis use and cannabis x gender predicted 
(a) emotional processing (as defined by components extracted from PCA) and (b) BDI-II 
scores. Aim 2. To determine the relationship between past year cannabis use, cannabis 
x gender, and brain structure: (a) Multiple regressions (including appropriate covariates) 
were used to predict bilateral mOFC, lOFC, Pars triangularis, superior temporal gyrus, 
fusiform gyrus, rACC, cACC, amygdala, hippocampus, and cerebellum volumes from 
past year cannabis use and cannabis x gender. (b) Multiple regressions (including 
appropriate covariates) were used to predict fractional anisotropy (FA) and mean 
diffusivity (MD) of the corpus callosum forceps minor, bilateral uncinate fasciculus, and 
bilateral anterior thalamic radiations from past year cannabis use and cannabis x 
gender. Main effects and covariates were entered into the first block; interaction 
variables were included in the second block. In order to assess if any participants 
disproportionately influenced the regression models, DFBETA analyses for past year 
cannabis use and cannabis x gender were conducted. One outlier for past year 
cannabis use was observed in predicting depressive symptoms; thus it was removed 
from the model. Results are reported with outliers removed. False Discovery Rate 
(FDR) correction (Benjamini & Hochberg, 1995 method) was conducted in Aims 1, 2a, 
and 2b. In aim 2a, FDR corrections were run separately for subcortical volume and 
cortical volume variables within each brain hemisphere (R/L) and white matter integrity 
variables. Additionally, f2 was used to assess effect sizes for multiple regression 
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analyses (small= 0.02-0.14, medium= 0.15-0.34, and large= >0.35) (Cohen et al., 
2003). 
     Secondary Analysis: Brain-Behavior Relationships. We conducted brain-
behavior analyses on brain regions that were significantly associated with past year 
cannabis use or cannabis x gender. For those regions that differed, we ran Pearson 
correlations within the cannabis group to determine whether brain abnormalities were 
related to (a) emotional processing and (b) BDI-II scores. For all analyses, significance 
was determined if p <0.05. 
 
Results 
Preliminary Results 
     Aim 1 Subgroup: Demographic Information (see Table 1). ANOVAs and chi-
square tests revealed no significant difference between cannabis users and non-users 
in age (F(1,75)= 1.17, p= .28), race (χ2(5)= 5.30, p=.38), ethnicity (χ2(2)= .92, p=.63), 
gender (χ2(1)= 2.50, p=0.11), and reading ability (F(1,75)= 1.81, p= .18).  
     Aim 1 Subgroup: Drug Use Information. Cannabis users and non-users 
significantly differed on measures of past year cannabis use (F(1,75)= 24.54, p<.01), 
past year alcohol use (F(1,75)= 15.18, p<.01) and past year nicotine use (F(1,75)= 7.61, 
p<.01). Past year alcohol and nicotine use were included as covariates in the 
regressions. 
     Aim 2 Subgroup: Demographic Information (see Table 1). ANOVAs and chi-
square tests revealed no significant difference between cannabis users and non-users 
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in age (F(1,73)= 0.98, p= .32), race (χ2(5)= 5.68, p=.34), ethnicity (χ2(2)= .92, p=.63), 
gender (χ2(1)= 1.88, p=0.24), and reading ability (F(1,73)= 1.54, p= .22).  
     Aim 2 Subgroup: Drug Use Information. Cannabis users and non-users 
significantly differed on measures of past year cannabis use (F(1,73)= 22.89, p<.01), 
past year alcohol use (F(1,73)= 14.58, p<.01), and past year nicotine use (F(1,73)= 
7.69, p<.01). Past year alcohol and nicotine use were included as covariates in the 
regressions. 
     Principal Components Analysis. Three principal components analyses (PCA) were 
conducted to reduce variables from the each of the tasks (Emotion Recognition, Acuity, 
and Discrimination) in the PennCNP affective battery. Variables with loadings > 0.6 
were considered to define a component. Emotion Recognition. For the Emotion 
Recognition task, nine variables were subjected to PCA with varimax rotation. This 
yielded four components meeting Kaiser’s criterion (eigenvalues >1). The following 
components were obtained (see Table 2): Recognition Time (29.54% of variance), 
Anger/Fear Correct (14.15% of variance), Sad Correct (13.91% of variance), and Happy 
Correct (12.57% of variance). These components accounted for 70.17% of the total 
variance observed in the Emotion Recognition variables. Emotional Acuity. Twelve 
variables were subjected to PCA for the Emotional Acuity task, yielding three 
components meeting Kaiser’s criterion (eigenvalues >1). Components included Acuity 
Time (34.32% of variance), Acuity Neutral (28.15% of variance), and Acuity Intensity 
(13.08% of variance) (see Table 3). Together, these components explained 75.55% of 
the variance observed. Emotion Discrimination. For the Emotion Discrimination task, 
eight variables underwent PCA with varimax rotation. Two components meeting 
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Kaiser’s criterion (eigenvalues >1) were obtained (see Table 4): Discrimination Time 
(46.72% of variance) and Discrimination Correct (33.86% of variance). These 
components accounted for 80.58% of the total variance. 
 
Primary Results (see Table 5 for significant findings) 
     All regions of interest demonstrating a significant relationship with either cannabis 
use or cannabis x gender are represented in Figure 1. Covariates included gender, past 
year alcohol use, and past year nicotine use. Intracranial volume (ICV) was included as 
an additional covariate in sMRI regressions. 
     Behavioral Outcomes. Cannabis. Past year cannabis use did not significantly 
predict Acuity Time [t (67) = .07, beta=.01, p=.95], Acuity Intensity [t (67) = 1.12, beta= 
.14, p=.30], Recognition Time [t (71) = -.34, beta= -.04, p=.73], Anger/Fear Correct [t 
(72) = 1.17, beta= .14, p=.25], Happy Correct [t (72) = .40, beta= .05, p=.69], Sad 
Correct [t (72) = .13, beta=.02, p=.90], Discrimination Time [t (72) = -.55, beta=-.07, 
p=.58], Discrimination Correct [t (72) = -.64, beta=-.08, p=.53], or depressive symptoms 
[t (71) = .84, beta=.11, p=.40]. Increased cannabis use was significantly associated with 
increased Acuity Neutral scores [t (67) = 2.02, beta= .25, p<.05, f2=.06, FDR-corrected: 
p=.47] (see Figure 2). Cannabis*Gender. Cannabis use and gender did not interact to 
predict Acuity Time [t (66) = .51, beta=.06, p=.62], Acuity Intensity [t (66) = -.54, beta= -
.07, p=.59], Acuity Neutral [t (66) = -.26, beta= -.03, p=.80], Recognition Time [t (71) = -
.17, beta=-.02, p=.87], Anger/Fear Correct [t (71) = .70, beta= .09, p=.49], Happy 
Correct [t (71) = -1.50, beta= -.18, p=.14], Sad Correct [t (71) = .62, beta=.08, p=.54], 
Discrimination Time [t (71) = 1.15, beta=.14, p=.25], and depressive symptoms [t (70) = 
	  	   25 
-.19, beta=-.03, p=.85]. Cannabis and gender marginally interacted to predict 
Discrimination Correct such that in females, greater cannabis use was associated with 
lower Discrimination Correct scores; males exhibited the opposite pattern [t (71) = -1.93, 
beta=-.23, p<.06]. Covariates. Gender significantly predicted Happy Correct, such that 
females had higher scores on this component compared to males [t (72) = 2.17, beta= 
.26, p= .03].  
     sMRI Outcomes. Cannabis. Past year cannabis use did not significantly predict left 
hippocampus [t (69) = 1.08, beta=.10, p=.29], right hippocampus [t (69) = -.31, beta=-
.03, p=.76], left amygdala [t (69) = 1.28, beta=.13, p=.21], right amygdala [t (69) = -.34, 
beta=-.04, p=.76], left cerebellum [t (69) = 1.24, beta=.11, p=.22], right cerebellum [t 
(69) = 1.57, beta=.14, p=.12], right cACC [t (69) = -.84, beta=-.09, p=.40], left cACC [t 
(69) = -1.19, beta=-.14, p=.24], right rACC [t (69) = .41, beta=.05, p=.68], right mOFC [t 
(69) = -.08, beta=-.01, p=.94], left mOFC [t (69) = -.51, beta=-.05, p=.61], left lOFC [t 
(69) = .29, beta=.03, p= .77], right pars triangularis [t (69) = -.85, beta=-.10, p=.40], left 
pars triangularis [t (69) = -1.00, beta=-.12, p=.32], right fusiform gyrus [t (69) = .45, 
beta=.04, p=.65], left fusiform gyrus [t (69) = -.28, beta=-.03, p=.78], and left superior 
temporal [t (69) = 1.35, beta=.12, p= .18] volumes. Increased past year cannabis use 
marginally predicted smaller right lOFC volumes [t (69) = -1.93, beta=-.18, p<.06]. 
Greater past year cannabis use significantly predicted smaller left rACC volumes [t (68) 
= -3.26, beta=-.29, p<.01, f2= .11; FDR corrected: p= 0.01] and larger right superior 
temporal volumes [t (69) = 2.27, beta=.19, p= .03, f2= .06; FDR corrected: p= 0.19] (see 
Figure 3). Cannabis*Gender. Cannabis use and gender did not interact to predict left 
hippocampus [t (68) = -1.04, beta=-.10, p=.30], right hippocampus [t (68) = .11, 
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beta=.01, p=.91], left amygdala [t (68) = -.22, beta=-.02, p=.83], right amygdala [t (68) = 
-.24, beta=-.03, p=.81], left cerebellum [t (68) = 1.06, beta=.10, p=.29], [t (68) = .17, 
beta=.02, p=.86], right cerebellum [t (68) = .17, beta=.02, p=.86], right cACC [t (68) = 
.30, beta=.03, p=.76], left cACC [t (68) = .69, beta=.08, p=.50], right rACC [t (68) = -
1.54, beta=-.17, p=.13], right mOFC [t (68) = .53, beta=.05, p=.60], left mOFC [t (68) = 
.84, beta=.08, p=.40], right lOFC [t (68) = .64, beta=.06, p=.53], left lOFC [t (68) = 1.12, 
beta=.67, p=.27], right pars triangularis [t (68) = .23, beta=.03, p=.82], left pars 
triangularis [t (68) = .18, beta=.02, p=.86], right fusiform gyrus [t (68) = -.24, beta=-.02, 
p=.81], left fusiform gyrus [t (68) = .47, beta=.04, p=.64], right superior temporal [t (68) = 
.98, beta=.08, p=.33], or left superior temporal [t (68) = -2.70, beta=-.26, p<.01] volume. 
Cannabis use and gender significantly interacted to predict left rACC volumes, such that 
only females demonstrated reduced volumes with increased cannabis use [t (68) = -
2.14, beta=-.19, p=.04, f2= .07; FDR corrected: p=.25] (See Figure 4). Covariates. 
Gender was significantly associated with left amygdala [t (69) = -2.13, beta=-.28, p=.04], 
left cerebellum [t (69) = -2.78, beta=-.34, p<.01], and right cerebellum [t (69) = -3.12, 
beta=-.37, p<.01] volumes, such that females exhibited smaller volumes compared to 
males.  
     DTI Outcomes. Cannabis. Past year cannabis use did not significantly predict right 
uncinate fasciculus FA [t (70) = .10, beta=.01, p= .92], right ATR FA [t (70) = -.08, beta= 
-.01, p= .94], right ATR MD [t (70) = -.95, beta= -.11, p= .35], left uncinate fasciculus FA 
[t (70) = -.01, beta=-.00, p= .99], left ATR FA [t (70) = .67, beta= .08, p= .50], left ATR 
MD [t (70) = -1.06, beta= -.13, p= .29], forceps minor FA [t (61) = -.05, beta=-.01, p= 
.96], or forceps minor MD [t (61) = -.84, beta=-.11, p= .40]. Cannabis use marginally 
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predicted left uncinate MD [t (70) = -1.85, beta=-.22, p= .07]. Greater cannabis use was 
significantly associated with reduced MD in the right uncinate fasciculus [t (70) = -2.00, 
beta=-.24, p= .05, f2= .06; FDR corrected: p= .34] (see Figure 5).  Cannabis*Gender. 
Cannabis*Gender did not significantly predict right uncinate fasciculus FA [t (69) = 1.19, 
beta=.15, p=.24], right uncinate fasciculus MD [t (69) = -.70, beta= -.08, p=.49], right 
ATR FA [t (69) = .54, beta=.06, p=.59], right ATR MD [t (69) = -.57, beta=-.07, p=.57], 
left uncinate fasciculus FA [t (69) = 1.22, beta=.15, p=.23], left uncinate fasciculus MD [t 
(69) = -.45, beta=-.05, p=.65], left ATR FA [t (69) = .21, beta=.02, p=.83], left ATR MD [t 
(69) = -.84, beta=-.10, p=.40], or forceps minor MD [t (60) = -.69, beta=-.09, p=.50]. 
Cannabis*Gender significantly predicted forceps minor FA, such that females 
demonstrated increased FA with more use while the opposite pattern was observed in 
males [t (60) = 2.06, beta=.26, p=.04, f2= .07; FDR corrected: p=.44] (see Figure 6). 
Covariates. Increased past year nicotine use was significantly associated with reduced 
right ATR FA [t (70) = -2.07, beta= -.24, p= .04]. Gender significantly predicted right [t 
(70) = 2.27, beta= .27, p= .03] and left [t (70) = 2.42, beta=.28, p=.02] ATR MD, such 
that females had higher values compared to males. Gender also significantly predicted 
left uncinate MD [t (70) = 2.14, beta=.25, p= .04] and left ATR FA [t (70) = -2.70, beta= -
.31, p<.01], such that males had higher values relative to females.  
 
Secondary Results (Brain-Behavior Relationships in Cannabis users) 
     Within cannabis users, smaller left rACC volumes were significantly associated with 
lower Discrimination Correct scores [r= .37, p= .04] (see Figure 7). Since 
cannabis*gender predicted left rACC volumes, the relationship between gender and left 
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rACC was explored. Within female cannabis users, smaller left rACC volumes 
significantly predicted lower Discrimination Correct scores [r= .68, p= .01]. Within male 
cannabis users, no significant relationship was observed between left rACC volume and 
Discrimination Correct scores [r= .31, p= .18]. No other affective measures were 
significantly associated with left rACC, right superior temporal volumes, or right uncinate 
fasciculus MD. 
Discussion 
     To our knowledge, this is the first study to assess the dose-dependent relationships 
between cannabis use, affective processing, and brain structure. Our first primary aim 
was to examine the association between cannabis use, depressive symptoms, and 
performance on an affective processing battery. Contrary to our predictions, we found 
that greater past year cannabis use predicted higher Acuity Neutral component scores. 
In the second primary aim, we investigated relationships between cannabis use and 
brain structures previously shown to be associated with affective processing. Most 
notably, increased past year cannabis use significantly predicted smaller left rACC 
volumes. Gender moderated this relationship such that only females exhibited 
significantly smaller left rACC volumes with increased cannabis use. Secondary 
analyses revealed that within the cannabis-using group, decreased left rACC volumes 
were significantly correlated with lower Discrimination Correct scores. This suggests 
that cannabis-related differences in the left rACC are associated with functional deficits. 
Past year cannabis use predicted larger right superior temporal volumes and lower MD 
in the right uncinate fasciculus. Finally, a significant cannabis x gender interaction was 
observed in the forceps minor, with females exhibiting increased FA with more use, 
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while the opposite pattern occurred in males. The only relationship that survived 
correction for multiple comparisons was the main effect of increased cannabis use 
predicting smaller left rACC volumes.  
     Our finding that greater cannabis use predicted higher scores on one component, 
Acuity Neutral, is, to our knowledge, the first report of chronic cannabis use being 
related to improved performance on an emotional faces task. This was in contrast to our 
hypothesis that chronic cannabis use would be associated with poorer affective 
processing due to downregulation of CB1 receptors in brain regions regulating affect 
(Hirvonen et al., 2012). In previous studies, cannabis users have exhibited deficits in 
facial emotion processing, although literature in this area is sparse (Platt et al., 2010; 
Hindocha et al., 2014; Huijbregts et al., 2014; Bayrakci et al., 2015). Hindocha et al. 
(2014) found that cannabis users were more impaired than controls in recognizing static 
facial emotions of moderate and higher intensity; this difference was not observed in 
processing more subtle emotions (20% emotional). Further, using a dynamic facial 
morphing task, Platt and colleagues (2010) found that cannabis users required a greater 
intensity of emotion for correct identification. Our findings deviate from both of these 
studies, in that cannabis use was not associated with more or less accurate intense 
emotion identification (Acuity Intensity component), but was associated with improved 
accuracy for subtle emotions (Acuity Neutral component). This may be due to 
differences in task construction (e.g., static versus dynamic stimuli, providing wider 
range of response options) across studies. 
     Another possible explanation is differences in cannabis exposure; mean use 
amongst cannabis users was higher (25-27 uses per month) in both the studies by 
	  	   30 
Hindocha et al. (2014) and Platt et al. (2010) compared to the current study (20 uses 
per month). Thus, it is possible that emotional face processing deficits are only 
observable in heavier (closer to daily) cannabis users. Some research suggests that 
adolescents who engage in a low to moderate level of cannabis use (no more than 
monthly) have improved interpersonal relations compared to those who abstain and 
heavier users (Shedler & Block, 1990). This may provide insight into the higher Acuity 
Neutral scores in the current study; 39.4% of the cannabis users in the current study 
used monthly or less frequently in the past year. Further, cannabis samples can vary 
widely in levels of THC and CBD (Swift et al., 2013), which may account for differences 
across studies. As acute CBD has been shown to improve facial affect recognition at 
moderate intensity (Hindocha et al., 2015), perhaps more participants in the current 
study used cannabis higher in CBD compared with participants in studies by Platt et al. 
(2010) and Hindocha et al. (2014). Future work will be needed in order to address this 
possibility. However, as the relationship between cannabis use and Acuity Neutral in the 
current study did not survive correction for multiple comparisons, it should be 
interpreted with caution.  
     Our most robust finding was that greater cannabis use was associated with reduced 
left rACC volumes, driven primarily by females. Null findings reported by other groups 
(Cousijn et al., 2012; Lorenzetti et al., 2015) may be due to the gender distribution. This 
finding is consistent with a recent report in young adult cannabis users with comorbid 
ADHD (Lisdahl et al., in press). Further, earlier age of cannabis use onset has been 
associated with reduced right rACC thickness within a sample of alcohol and cannabis 
using adolescents (Jacobus et al., 2014). Additionally, research amongst psychosis 
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patients has revealed cannabis-dependent relationships with decreased bilateral ACC 
volumes (Szeszko et al., 2007), left ACC volumes (Rapp et al., 2013), and increased 
cortical thinning in the left ACC during the first five years of schizophrenia (Rais et al., 
2010). Thus, the evidence suggests that chronic cannabis use is related to reductions in 
ACC gray matter, particularly in the left hemisphere. This may be because the left 
hemisphere contains a higher CB1 receptor density (Glass et al., 1997). The ACC itself 
is rich in CB1 receptors (Herkenham et al., 1990; Glass et al., 1997) and chronic 
cannabis use leads to downregulation of CB1 receptors in the cingulate cortex 
(Hirvonen et al., 2012). The eCB system modulates synaptic plasticity and, via CB1 
receptors on glial cells, neuronal support (Pazos et al., 2005; Melis et al., 2014). Thus, 
CB1 downregulation may lead to reduced dendritic branching or neuronal atrophy, 
resulting in gray matter reductions (Lisdahl et al., 2014). Importantly, females may have 
increased CB1 desensitization to THC in frontolimbic regions compared to males 
(Crane et al., 2013). This may explain why females, but not males, in the current study, 
demonstrated smaller left rACC volumes with increased cannabis exposure. Further, 
reduced left rACC volumes were related to lower Discrimination Correct scores within 
cannabis using females, but not males. This is consistent with other studies showing 
volumetric differences in the PFC and amygdala associated with functional deficits in 
female, but not male, cannabis users (Medina et al., 2009; McQueeny et al., 2011).  
     The link between exogenous cannabinoids, the ACC, and emotion processing has 
been previously documented. Chronic cannabis users, compared to healthy controls, 
have demonstrated altered ACC activation to masked emotional faces (Gruber et al., 
2009) and ACC hypoactivity in response to emotional scenes (Wesley et al., 2016). 
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Acute THC administration enhanced functional connectivity between the rACC/mPFC 
and amygdala during an emotion discrimination task in which participants were 
instructed to decide which of two emotional (angry, fearful, or happy) faces matched a 
third face (Gorka et al., 2015). On the other hand, acute CBD has been shown to 
attenuate ACC activation and decrease connectivity between the ACC and amygdala in 
response to fearful faces (Fusar-Poli et al., 2009; Fusar-Poli et al., 2010). The present 
study supplements the fMRI literature by providing evidence for left rACC structural 
abnormalities with chronic cannabis use in association with abnormal affective 
processing. Notably, cannabis use predicted rostral, but not caudal ACC volumes. 
Substantial past work suggests the rostral portion of the ACC supports emotional 
processing, while the caudal region contributes more to cognitively demanding tasks by 
influencing response selection, error detection, working memory, and monitoring 
competition (Devinsky et al., 1995; Bush et al., 2000). Given the specialization of the 
rACC, it is unsurprising that reduced left rACC volumes were associated with lower 
Emotion Discrimination Correct scores in cannabis using females.  
     It is worth considering why Discrimination Correct was the only affective measure for 
which a relationship was observed with left rACC. Perhaps the rACC serves a crucial 
function in an aspect of the Emotion Discrimination task that is not present in the other 
tasks. For example, it is possible that the rACC is critical in comparing two emotional 
stimuli and making a decision regarding them. Previous research has identified the ACC 
as important in emotion discrimination when one is presented with multiple faces 
(Munro et al., 2007). Additionally, research suggests a role for the rACC in shifting 
attention toward or away from emotional faces (Klumpp et al., 2012), which may be 
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important if attending to multiple faces simultaneously. Another possibility is that the 
Emotion Discrimination task was more difficult compared to the Emotion Recognition 
and Emotional Acuity tasks, and thus the Discrimination task was more sensitive to 
rACC abnormalities. In functional neuroimaging studies of cannabis users, aberrant 
activation patterns often occur without differences in task performance (e.g., Cousijn et 
al., 2014; Wesley et al., 2016), suggesting that cannabis users may be able to 
compensate by adjusting which regions are recruited for a particular task. Thus, 
perhaps female cannabis users in our sample were able to rely more heavily on other 
brain areas besides the rACC while completing the Emotion Recognition and Emotional 
Acuity tasks, but not the Emotion Discrimination task. However, a functional 
neuroimaging study would be necessary in order to address this possibility. 
     Greater past year cannabis use also predicted larger right superior temporal 
volumes, although this was not related to any affective processing measure in the 
current sample. One past investigation revealed no superior temporal volume 
alterations in cannabis users (DeLisi et al., 2006). However, others have reported 
increased cortical thickness in the superior temporal gyrus in cannabis users compared 
to non-users (Lopez-Larson et al., 2011; Epstein & Kumra, 2015). Moreover, adolescent 
cannabis users have reduced cerebral blood flow in the left superior temporal gyrus 
prior to abstinence (Jacobus et al., 2012), which may impact synaptic pruning 
(Takahashi et al., 1999). Thus, structural aberrations in the superior temporal gyrus 
could reflect insufficient synaptic pruning related to cannabis use. Alternatively, 
increased right superior temporal volumes may indicate abnormal connectivity patterns 
(Lisdahl et al., 2014), in which this region compensates for reduced efficiency in other 
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regions more susceptible to exogenous cannabinoids, such as the PFC (Mackie et al., 
2005). Yet, it is not possible to conclude that this association between cannabis use and 
increased superior temporal volumes reflects cortical damage or compensation without 
evidence for behavioral deficits in our sample. Importantly, the association between 
cannabis use and the superior temporal region did not survive correction for multiple 
comparisons, indicating it may be a spurious finding. The superior temporal region is 
involved in facial perception, auditory processing, and multisensory audiovisual 
language processing (Ishai et al., 2005; Gazzaniga et al., 2014). Thus, future studies 
should continue to investigate these functions in cannabis users in relation to superior 
temporal areas. 
     The uncinate fasciculus is a tract connecting the anterior temporal lobe with frontal 
regions, passing through the amygdala (Catani & Thiebaut de Schotten, 2012; Von Der 
Heide et al., 2013). It supports episodic memory, language, and socio-emotional 
processing (Von Der Heide et al., 2013). In contrast to our hypothesis, cannabis use 
was significantly related to increased integrity, indicated by decreased mean diffusivity, 
in the right uncinate fasciculus. Most studies have shown cannabis use to be associated 
with decreased white matter integrity in various tracts, including in the uncinate 
fasciculus (e.g., Jacobus et al., 2013a). Our own group found increased MD and 
decreased FA in the uncinate fasciculus in a different sample of young adult cannabis 
users (Shollenbarger et al., 2015). Importantly, mean past year use cannabis use 
amongst users in that sample (548 joints) was more than double the amount in the 
current study (228 joints). Therefore, it is possible that at lower doses, cannabis use 
may actually improve white matter integrity. In fact, others have also noted increased 
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white matter integrity in association with cannabis use, although in a different tract 
(forceps minor) (Filbey et al., 2014). Cannabis has anti-inflammatory properties and has 
been shown to specifically decrease inflammation in myelin, a major component of 
white matter (for review, Burstein, 2015; Kozela et al., 2015). Reduced inflammation 
leads to decreased tissue water and diffusion, which results in lower MD values 
(Alexander et al., 2007). Additionally, cannabinoids possess neuroprotective and 
antioxidant properties that may benefit white matter (Karl et al., 2012). Another 
possibility is that the right uncinate fasciculus has abnormally strong connectivity in 
order to compensate for observed structural abnormalities in the right temporal region, 
which it connects with the PFC. Perhaps this initial compensation disappears with 
heavier cannabis use. Age of cannabis use onset may also influence white matter 
integrity and lead to differences in findings. Mean age of onset amongst cannabis users 
in the present study as well as in the study by Filbey and colleagues (2014) was 
relatively high at 17 and 18 years, respectively. Further, eCB genetics (i.e., FAAH 
genotype) has been shown to moderate white matter integrity in cannabis users 
(Shollenbarger et al., 2015). However, the relationship between greater cannabis use 
and reduced right uncinate fasciculus MD did not survive correction for multiple 
comparisons and as such, is of limited interpretability. 
     Cannabis use and gender interacted to predict forceps minor FA, such that females 
tended to have increased FA with more use, while the opposite pattern was observed in 
males. Previous studies demonstrated reduced white matter integrity in the forceps 
minor (Jacobus et al., 2013; Shollenbarger et al., 2015) and anterior portions of the 
corpus callosum (Arnone et al., 2008; Gruber et al., 2011; Gruber et al., 2014) in 
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cannabis users compared to controls. Yet, increased forceps minor FA aligns with 
Filbey and colleagues’ (2014) findings, although this was observed as a main effect in 
their entire sample, which was predominantly male. The forceps minor is a fiber bundle 
connecting the frontal lobes, including the rACC (Catani & Thiebaut de Schotten, 2012). 
It is possible that females with greater cannabis use exhibited increased FA in the 
forceps minor in order to compensate for reductions in rACC volume and function, while 
this was not necessary for males, who did not exhibit rACC effects. As the rACC is high 
in CB1 receptor density, perhaps the forceps minor is able to uniquely adjust to 
exogenous cannabinoid influence (Filbey et al., 2014). Another possibility is that males 
were more susceptible than females to the negative effects of cannabis on the forceps 
minor, as frontal white matter takes longer to develop in males compared to females 
(Simmonds et al., 2014). Further, factors such as THC: CBD ratios and genetics may 
have differed between males and females in our sample, driving these differences in 
FA. Additionally, this finding may be spurious as it did not survive correction for multiple 
comparisons. 
     The present study has some important limitations. Firstly, in order to address 
whether through use of PCA, more subtle behavioral relationships were missed, 
supplementary regressions were run for cannabis use predicting individual PennCNP 
variables. The only significant relationships were with Emotional Acuity Total Correct 
and Emotional Acuity Happy Neutral Correct, which both loaded onto the Acuity Neutral 
component, indicating that all variables demonstrating a significant relationship with 
cannabis use were represented in components yielding significance. Second, due to the 
cross-sectional, correlational nature of the study, it is not possible to determine the 
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causal nature of the relationship between cannabis use and outcome variables. Further, 
the cannabis exposure was lower than what is typically reported in previous publications 
(average exposure 228 past year joints, with 39.4% using monthly or less frequently 
and 24.2% using daily or more); therefore, these results may not generalize to young 
adults with heavier use patterns. Similarly, length of cannabis abstinence was much 
longer in our sample compared with most previous research (mean length of abstinence 
57 days, minimum of 19 days). In most studies, users are abstinent for an average of 2-
3 days, and research suggests there may be significant recovery with abstinence 
(Lisdahl et al., 2014; D’Souza et al., 2016). Additionally, only one relationship (cannabis 
predicting left rACC volumes) survived correction for multiple comparisons. As such, the 
other significant associations found may be spurious and must be interpreted with 
caution. We did not meet the sample size recommended (N=133) for 80% power at the 
smallest effect size observed (f2=0.06); therefore, we only had adequate power 
(recommended N= 74) for the effect size observed in the rACC (f2=0.11). Two brain 
region measures, right lOFC volume and left uncinate fasciculus MD, exhibited trend 
level relationships (p= 0.058 and p= 0.06, respectively) with past year cannabis use. It is 
possible that with a larger sample size, significant effects may have been revealed. 
Therefore, these findings should be replicated in a larger sample for increased power. 
Finally, considering the study’s naturalistic design, there may other variables, including 
age, genetics, THC:CBD ratios (for reviews, see Niesink & van Laar, 2013; Lorenzetti et 
al., 2016), sex hormones, and physical fitness levels (Herting et al., 2012), moderating 
the results. Future research should use longitudinal designs with larger sample sizes 
and also measure these potential moderators.  
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     The current study provides evidence for a relationship between past year cannabis 
use and reduced left rACC volumes in females, larger superior temporal volumes, and 
decreased right uncinate fasciculus MD. Gender moderated the relationship between 
cannabis use and forceps minor FA, with females demonstrating increased FA with 
more use and males demonstrating the opposite relationship. Our most clinically 
relevant and robust finding was greater past year cannabis use predicting smaller left 
rACC volumes and within cannabis users, smaller left rACC volumes being associated 
with lower scores on the Discrimination Correct component. Thus, chronic cannabis use 
during adolescence and emerging adulthood, a time of continued neurodevelopment 
(Casey et al., 2008), may negatively impact brain regions important for affective 
processing. These neural abnormalities, in turn, are associated with difficulty 
discriminating emotions, which may negatively influence mood and emotional well-being 
(Phillips et al., 2003). Given the potential negative consequences of cannabis use as 
evidenced by current and prior findings, more research on interventions for cannabis 
use in youth is needed. 
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Tables 
Table 1 
Participant Demographics 
 Aim 1: Affective/Behavioral (N=77) Aim 2: Brain Structure (N=75) 
 
Cannabis Users 
(n=33) 
Non-Users 
(n=44) 
Cannabis Users (n=32) Non-Users (n=43) 
 
% or M + SD 
(range) 
% or M + SD 
(range) 
% or M + SD (range) % or M + SD (range) 
Gender (% female) 36.4% 54.5% 37.5% 53.5% 
Race (% Caucasian) 65.9% 69.7% 68.8% 67.4% 
Ethnicity (% Non-
Hispanic) 
87.9% 88.6% 87.5% 88.4% 
Age (years) 21.6±2.2 (18-26) 21.0±2.7 (16-25) 21.6 ± 2.2 (18-26) 21.0±2.7 (16-25) 
WRAT-4 (raw score) 60.7±5.2 (41-69) 
62.0 ±3.7 (53-
69) 
60.7 ± 5.3 (41-69) 62.0 ±3.8 (53-69) 
Beck Depression 
Inventory-II (BDI-II) 
5.7 ± 4.6 (0-18)* 2.6 ± 3.1 (0-10)* 5.8 ± 4.7 (0-18)* 2.6 ± 3.1 (0-10)* 
Age of weekly 
cannabis use onset 
(years) 
17.5 ± 1.8 (13-21) - 17.5 ± 1.8 (13-21) - 
Lifetime cannabis use 
(uses) 
796.45 ± 1095.9 
(25-6000)* 
3.4 ± 6.8 (0-25)* 
790.1  ± 1112.8 (25-
6000)* 
3.4 ± 6.8 (0-25)* 
Past year cannabis use 
(joints) 
228.6 ± 306.2 (0-
1394)* 
0.4 ± 1.1 (0-5)* 226.8 ± 310.9 (0-1394)* 0.4 ± 1.1 (0-5)* 
Length of cannabis 
abstinence at Session 
4 (days) 
57.2 ± 85.9 (19-
422) 
- 58.1 ± 87.1 (19-422) - 
Past year alcohol use 
(standard drinks) 
313.2 ±272.9 (0-
897)* 
112.4 ± 178.8 
(0-698.5)* 
316.4 ± 276.7 (0-897)* 
114.7 ± 180.2 (0-
698.5)* 
Past year nicotine use 
(cigarettes) 
143.4 ±344.4 (0-
1165)* 
0.5 ±1.9 (0-12)* 147.8 ± 348.9 (0-1165)* 0.5 ±1.9 (0-12)* 
Session 4 cotinine 
levels (0-6) 
2.06 ± 1.7 (0-6)* 1.09 ± .6 (0-3)* 2.10 ± 1.7 (0-6)* 1.09 ± .6 (0-3)* 
Session 5 cotinine 
levels (0-6) 
2.03 ± 1.6 (0-6)* 1.09 ± .7 (0-3)* 2.03 ± 1.6 (0-6)* 1.09 ± .7 (0-3)* 
% Positive THC Urine 
Toxicology Session 1 
54.5%* 0%* 53.1%* 0%* 
% Positive THC Urine 3% 0% 3.1% 0% 
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Note. *Group differences: p< .05.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxicology Session 4 
% Positive THC Urine 
Toxicology Session 5 
- - 3.1% 0% 
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Table 2. Emotion Recognition Principal Components Analysis Factor Loadings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Component Labels 
Variable Recognition 
Time 
Anger/Fear 
Correct 
Sad 
Correct 
Happy 
Correct 
Anger Correct .121 .849 -.152 -.156 
Fear Correct -.262 .627 .328 .323 
Sad Correct -.001 -.021 .935 .003 
Happy Correct .031 -.018 -.001 .950 
Anger Correct Median      
Response Time (ms) 
.660 .107 -.296 -.033 
Fear Correct Median 
Response Time (ms) 
.725 -.362 .014 -.261 
Sad Correct Median 
Response Time (ms) 
.611 -.007 -.099 -.026 
Happy Correct Median 
Response Time (ms) 
.765 .107 .380 -.009 
Neutral Correct Median 
Response Time (ms) 
.809 -.071 .069 .173 
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Table 3. Emotional Acuity Principal Components Analysis Factor Loadings 
 
 
 Component Labels 
Variable Acuity Time Acuity Neutral Acuity Intensity 
Total Correct -.096 .915 .380 
Very Happy Correct -.074 -.093 .758 
Happy Neutral Correct -.003 .879 -.129 
Neutral Correct -.154 .940 -.135 
Sad Neutral Correct -.252 .746 -.025 
Very Sad Correct .163 .076 .747 
Correct Trials Median Response Time 
(ms) 
.947 -.199 .148 
Correct Very Happy Trials Median 
Response Time (ms) 
.806 .112 -.245 
Correct Happy Neutral Trials Median 
Response Time (ms) 
.744 -.388 .173 
Correct Neutral Trials Median 
Response Time (ms) 
.887 -.293 .182 
Correct Sad Neutral Trials Median 
Response Time (ms) 
.860 -.155 .265 
Correct Very Sad Trials Median 
Response Time (ms) 
.603 .015 -.206 
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Table 4.  
 
Emotion Discrimination Principal Components Analysis Factor Loadings 
 
 Component Labels 
Variable Discrimination Time Discrimination Correct 
Total Correct .094 .989 
Happy Trials Correct .114 .896 
Sad Trials Correct .041 .844 
Correct Happy Trials Median Response 
Time (ms) 
.921 -.013 
Incorrect Happy Trials Median 
Response Time (ms) 
.726 .375 
Correct Sad Trials Median Response 
Time (ms) 
.886 -.019 
Incorrect Sad Trials Median Response 
Time (ms) 
.778 .271 
Total Correct Trials Median Response 
Time (ms) 
.974 -.017 
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Table 5.  
 
Significant Relationships Observed With p-values Before and After Correcting for 
Multiple Comparisons 
 
Relationship p-value Effect Size 
(f2) 
FDR-corrected 
p-value 
Cannabis àAcuity Neutral Component 0.047* .06 0.470 
CannabisàLeft rACC volume 0.002* .11 0.014* 
Cannabis*GenderàLeft rACC volume 0.036* .07 0.252 
Cannabisà Right superior temporal volume 0.027* .06 0.189 
Cannabisà Right uncinate MD 0.050* .06 0.340 
Cannabis*Genderàforceps minor FA 0.044* .07 0.440 
Note. *p< .05. 
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Figures 
 
 
Figure 1. All regions of interest that demonstrated a significant relationship with either 
cannabis use or cannabis x gender prior to correction for multiple comparisons are 
presented here on representative participants. A) Increased cannabis use and gender 
significantly interacted to predict smaller left rACC volumes, such that only females 
demonstrated this relationship. The left rACC is shown in red on this sagittal slice. B) 
Greater cannabis use was associated with larger right superior temporal volumes, 
highlighted in blue. C) This axial slice presents a ventral view of the brain. Increased 
cannabis use was related to decreased right uncinate fasciculus (shown in blue) MD; 
gender moderated the relationship between cannabis use and forceps minor (red) FA, 
such that males had decreased FA with more cannabis use and females exhibited the 
opposite pattern.  
A B 
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Figure 2. After controlling for gender, past year alcohol use, and past year nicotine use, 
a dose-dependent relationship was observed between greater past year cannabis use 
and higher scores on the Acuity Neutral component. 
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Figure 3. After controlling for gender, past year alcohol use, and past year nicotine use, 
increased past year cannabis use was associated with larger right superior temporal 
volumes. However, this relationship did not survive correction for multiple comparisons. 
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Figure 4. Greater past year cannabis use significantly predicted smaller left rostral ACC 
volumes. Gender significantly moderated this relationship, such that in females, 
cannabis use was associated with reduced volumes, while in males, no significant 
association between cannabis use and left rACC emerged. Covariates included gender, 
past year alcohol use, and past year nicotine use. The main effect (cannabis use 
predicting left rACC volumes) survived FDR corrections; however, the cannabis*gender 
interaction was no longer significant after correcting for multiple comparisons. 
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Figure 5. Greater past year cannabis use was significantly associated with reduced 
mean diffusivity in the right uncinate fasciculus, indicating increased integrity. 
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Figure 6. Cannabis*Gender significantly predicted fractional anisotropy (FA) in the 
corpus callosum forceps minor, such that males exhibited reduced FA with increased 
use; females had higher FA with increased cannabis use. 
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Figure 7. Within the cannabis-using group, Pearson correlations revealed that smaller 
left rACC volumes were associated with lower scores on the Discrimination Correct 
component.   
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